The US Food and Drug Administration (FDA) has extended Regenxbio’s review timeline of the Biologics License Application (BLA) ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...

Boehringer Ingelheim & AnGes sign manufacturing agreement for HGF gene therapy product: Ingelheim, Germany Thursday, August 21, 2025, 09:00 Hrs [IST] Boehringer Ingelheim, a bioph ...

US FDA extends review timeline of Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II: Rockville, Maryland Wednesday, August 20, 2025, 18:00 Hrs [IST] ...

The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form.

WuXi has a wide range of technical platforms for state-of-the-art biologic innovations, including the bispecific and multispecific antibodies platform under WuXiBody, the Chinese hamster ovary ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea ...

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its ...

Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing ...

The Business Research Company The Business Research Company's Asthma Disease Market Trends and Analysis by Application, Vertical, Region, a ...